Skip to main content

and
  1. Article

    Open Access

    Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis

    Sonidegib is approved to treat locally advanced basal cell carcinoma (laBCC) in the USA, EU, Switzerland, and Australia and metastatic basal cell carcinoma (mBCC) in Switzerland and Australia in patients not a...

    Ralf Gutzmer, Carmen Loquai, Caroline Robert, Brigitte Dréno in Dermatology and Therapy (2021)

  2. Article

    Open Access

    Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629

    At first interim analysis of KEYNOTE-629, health-related quality of life (HRQoL) with pembrolizumab was stable or improved over 48 weeks in recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC...

    Åse Bratland, Eva Munoz-Couselo, Laurent Mortier, Osama Roshdy in Dermatology and Therapy (2023)